NowenFlow Neuroscience Unclaimed
Flow Neuroscience develops FDA-approved at-home neuromodulation therapies for adults with depression.
Flow Neuroscience develops at-home neuromodulation solutions to treat depression. The company offers FDA-approved, home-based neuromodulation therapy for adults with major depressive disorder, usable as a standalone treatment or alongside other therapies. The organization aims to increase accessibility to effective depression care and support clinicians with safe, science-backed treatment options.
To provide accessible, evidence-based, FDA-approved neuromodulation treatments for people living with depression.
What we offer
Flow FL-100
FDA-approved at-home treatment for depression offered as monotherapy or adjunct therapy.
www.flowneuroscience.com/efficacy-and-outcomes-flow-neuroscience?hsLang=en-usMarket segments
At-home neuromodulation for major depressive disorder
Home-administered, FDA-approved neuromodulation therapy for adults with moderate to severe major depressive disorder that can be used as monotherapy or adjunctive treatment to expand access to evidence-based care.
Prescription neuromodulation devices for clinical practice
Clinician-prescribed neuromodulation devices integrated into outpatient care pathways for depression, supported by randomized trial evidence and real-world safety data to inform treatment planning.
Adjunctive treatment to antidepressant therapy
Therapies used alongside antidepressant medications to improve clinical response and reduce suicidal ideation, backed by clinical trial and real-world outcome data.
Remote depression care and maintenance therapy
Remote-managed, home-based interventions for ongoing symptom management and maintenance treatment to improve continuity of care and access for adults with MDD, informed by real-world user data.
More information about our offering
Flow FL-100
Flow FL-100 is an FDA-approved, home-based neuromodulation treatment for adults 18 and older with moderate to severe Major Depressive Disorder. It can be used as a monotherapy or as an adjunct to antidepressant therapy, without requiring prior medication failure. The device is designed for at-home use and supports Flow Neuroscience’s aim to broaden access to effective depression care. Evidence from a multisite, double-blind, randomized trial shows Flow FL-100 is effective when used as both a standalone treatment and an adjunct to antidepressant therapy at 10 weeks. Real-world data from over 40,000 users indicate a favorable safety profile with a low incidence of adverse reactions (4.5%).
- Demonstrates Proven EffectivenessResults from a rigorous clinical trial validate the efficacy of Flow FL-100 as both a standalone treatment and when used alongside traditional antidepressants.
- Enables At-Home TreatmentFacilitates convenient access to depression treatment within the comfort of home, improving adherence and comfort.
- Significantly Reduces Suicidal IdeationDemonstrates the potential of Flow FL-100 in providing critical support for individuals in crisis.
- Targets Adult PopulationSpecifically designed to meet the needs of adults suffering from significant depressive symptoms.
- Offers Treatment FlexibilityProvides a versatile treatment approach that accommodates varying patient needs and treatment histories.
- Ensures Safety During UseData suggest a minimal risk of side effects, supporting its safety for users.
- Awareness of Upcoming LaunchKeeps potential users informed about the anticipated timeline for accessing this innovative treatment in the U.S.